126 related articles for article (PubMed ID: 38565464)
1. Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda.
Kimbugwe G; Vatrinet R; Mwanga JA; Kakuru R; Mpeirwe D; Logoose S; Opio K; Kambale M; Seeley J; Grais RF; Marquer C; Kaleebu P; Ssali A
Vaccine; 2024 Apr; 42(12):3002-3008. PubMed ID: 38565464
[TBL] [Abstract][Full Text] [Related]
2. Perceptions and acceptability of an experimental Ebola vaccine among health care workers, frontline staff, and the general public during the 2014-2015 Ebola outbreak in Sierra Leone.
Jalloh MF; Jalloh MB; Albert A; Wolff B; Callis A; Ramakrishnan A; Cramer E; Sengeh P; Pratt SA; Conteh L; Hajjeh R; Bunnell R; Redd JT; Ekström AM; Nordenstedt H
Vaccine; 2019 Mar; 37(11):1495-1502. PubMed ID: 30755367
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea.
Grantz KH; Claudot P; Kambala M; Kouyaté M; Soumah A; Boum Y; Juan-Giner A; Jemmy JP; Cummings DAT; Grais RF
Vaccine; 2019 Nov; 37(48):7165-7170. PubMed ID: 31623917
[TBL] [Abstract][Full Text] [Related]
4. Willingness to participate in Ebola viral disease vaccine trials and receive vaccination by health workers in a tertiary hospital in Ile-Ife, Southwest Nigeria.
Olowookere SA; Abioye-Kuteyi EA; Adekanle O
Vaccine; 2016 Nov; 34(47):5758-5761. PubMed ID: 27751640
[TBL] [Abstract][Full Text] [Related]
5. Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
Boum Y; Juan-Giner A; Hitchings M; Soumah A; Strecker T; Sadjo M; Cuthbertson H; Hayes P; Tchaton M; Jemmy JP; Clarck C; King D; Faga EM; Becker S; Halis B; Gunnstein N; Carroll M; Røttingen JA; Kondé MK; Doumbia M; Henao-Restrepo AM; Kieny MP; Cisse M; Draguez B; Grais RF
Vaccine; 2020 Jun; 38(31):4877-4884. PubMed ID: 32499066
[TBL] [Abstract][Full Text] [Related]
6. Acceptability and Willingness-to-Pay for a Hypothetical Ebola Virus Vaccine in Nigeria.
Ughasoro MD; Esangbedo DO; Tagbo BN; Mejeha IC
PLoS Negl Trop Dis; 2015 Jun; 9(6):e0003838. PubMed ID: 26076007
[TBL] [Abstract][Full Text] [Related]
7. Knowledge and attitudes about Ebola vaccine among the general population in Sierra Leone.
Huo X; Shi G; Li X; Lai X; Deng L; Xu F; Chen M; Wei Q; Samba T; Liang X
Vaccine; 2016 Apr; 34(15):1767-72. PubMed ID: 26928073
[TBL] [Abstract][Full Text] [Related]
8. Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.
Juan-Giner A; Tchaton M; Jemmy JP; Soumah A; Boum Y; Faga EM; Cisse M; Grais RF
Vaccine; 2019 Nov; 37(48):7171-7177. PubMed ID: 30266489
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
Anywaine Z; Whitworth H; Kaleebu P; Praygod G; Shukarev G; Manno D; Kapiga S; Grosskurth H; Kalluvya S; Bockstal V; Anumendem D; Luhn K; Robinson C; Douoguih M; Watson-Jones D
J Infect Dis; 2019 Jun; 220(1):46-56. PubMed ID: 30796818
[TBL] [Abstract][Full Text] [Related]
11. Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey.
Dayer JA; Siegrist CA; Huttner A
PLoS One; 2017; 12(3):e0173148. PubMed ID: 28273130
[TBL] [Abstract][Full Text] [Related]
12. Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda.
Kitonsa J; Ggayi AB; Anywaine Z; Kisaakye E; Nsangi L; Basajja V; Nyantaro M; Watson-Jones D; Shukarev G; Ilsbroux I; Robinson C; Kaleebu P
Glob Health Action; 2020 Dec; 13(1):1829829. PubMed ID: 33073737
[TBL] [Abstract][Full Text] [Related]
13. Attitudes about vaccines to prevent Ebola virus disease in Guinea at the end of a large Ebola epidemic: Results of a national household survey.
Irwin KL; Jalloh MF; Corker J; Alpha Mahmoud B; Robinson SJ; Li W; James NE; Sellu M; Jalloh MB; Diallo AA; Tracy L; Hajjeh R; VanSteelandt A; Bunnell R; Martel L; Raghunathan PL; Marston B;
Vaccine; 2017 Dec; 35(49 Pt B):6915-6923. PubMed ID: 28716555
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Mwesigwa B; Houser KV; Hofstetter AR; Ortega-Villa AM; Naluyima P; Kiweewa F; Nakabuye I; Yamshchikov GV; Andrews C; O'Callahan M; Strom L; Schech S; Anne Eller L; Sondergaard EL; Scott PT; Amare MF; Modjarrad K; Wamala A; Tindikahwa A; Musingye E; Nanyondo J; Gaudinski MR; Gordon IJ; Holman LA; Saunders JG; Costner PJM; Mendoza FH; Happe M; Morgan P; Plummer SH; Hickman SP; Vazquez S; Murray T; Cordon J; Dulan CNM; Hunegnaw R; Basappa M; Padilla M; Gajjala SR; Swanson PA; Lin BC; Coates EE; Gall JG; McDermott AB; Koup RA; Mascola JR; Ploquin A; Sullivan NJ; Kibuuka H; Ake JA; Ledgerwood JE;
Lancet Infect Dis; 2023 Dec; 23(12):1408-1417. PubMed ID: 37544326
[TBL] [Abstract][Full Text] [Related]
15. Considerations for use of Ebola vaccine during an emergency response.
Walldorf JA; Cloessner EA; Hyde TB; MacNeil A;
Vaccine; 2019 Nov; 37(48):7190-7200. PubMed ID: 28890191
[TBL] [Abstract][Full Text] [Related]
16. Implementing a Multisite Clinical Trial in the Midst of an Ebola Outbreak: Lessons Learned From the Sierra Leone Trial to Introduce a Vaccine Against Ebola.
Carter RJ; Idriss A; Widdowson MA; Samai M; Schrag SJ; Legardy-Williams JK; Estivariz CF; Callis A; Carr W; Webber W; Fischer ME; Hadler S; Sahr F; Thompson M; Greby SM; Edem-Hotah J; Momoh RM; McDonald W; Gee JM; Kallon AF; Spencer-Walters D; Bresee JS; Cohn A; Hersey S; Gibson L; Schuchat A; Seward JF
J Infect Dis; 2018 May; 217(suppl_1):S16-S23. PubMed ID: 29788343
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
[TBL] [Abstract][Full Text] [Related]
18. Assessment of health care workers preparedness to epidemics: A case of Ebola virus disease preparedness in private hospitals in Kampala, Uganda.
Ankunda C; Kanyesigye SM; Nakubulwa S; Kyomuhangi B; Cramer J; Chacon-Cruz E; Clemens SAC; Clemens R
J Infect Dev Ctries; 2024 Apr; 18(4):556-564. PubMed ID: 38728629
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
[TBL] [Abstract][Full Text] [Related]
20. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Mbaye KD; Thiongane A; Ndiaye BP; Ndour CT; Mboup S; Keshinro B; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Gobert P; Hogrefe WR; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):719-730. PubMed ID: 32199492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
